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To assess the imaging features of hypovascular borderline lesions containing 
hypervascular foci on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), and to evaluate the 
ability of Gd-EOB-DTPA-enhanced MRI to diagnose high-risk borderline lesions 
possibly consistent with early HCC. 
 
Methods:  
Institutional review board approval was obtained for this retrospective analysis of 
imaging findings, and informed consent was obtained from 217 consecutive patients 
undergoing Gd-EOB-DTPA-enhanced MRI and angiography-assisted computed 
tomography (CT) for examination of hepatocellular nodular lesions in cirrhotic livers. 
There were 73 nodules showing hypervascular foci in borderline lesions identified by 
angiography-assisted CT. Signal intensity patterns of the nodules were evaluated on 
hepatobiliary phase Gd-EOB-DTPA-enhanced T1-weighted MRI obtained 20 minutes 
after intravenous (IV) injection of contrast media.  
 
Results:  
Among 73 high-risk borderline lesions, 59 were hypointense (81%) and 14 were 
isointense (19%), compared to background liver parenchyma. There were 27 untreated 
lesions followed by CT and/or MRI. Almost half of these nodules transformed into 




Although many high-risk borderline HCC lesions are hypointense on hepatobiliary 
phase Gd-EOB-DTPA-enhanced MRI, some high-risk borderline lesions are isointense 
and transform at the same rate into hypervascular HCC. 
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 INTRODUCTION 
Hepatocellular carcinoma (HCC) is the fifth most common tumor in the world, and is 
the third most common cause of cancer-related death, after lung and stomach cancer1. 
Based on clinical and histopathological analyses, most HCC develops from chronic liver 
disease in a multistep process2,3. The spectrum of hepatocellular nodules ranges from 
benign regenerative lesions to classic HCC demonstrating vascular invasion and distant 
metastasis, with intermediate steps including low- and high-grade dysplastic nodules 
(DNs) and early HCC4. Among these nodules, high-grade DN and early HCC are now 
considered to be the precursors of classic HCC, and show a multistep progression from 
high-grade DN to early HCC to classic HCC. These high-grade DNs and early HCCs are 
called “borderline lesions” in clinical practice because they are difficult to differentiate 
by imaging and biopsy, and because of their biologically benign nature. The detection 
and characterization of early HCC is important because of its much higher potential for 
progression to classic invasive HCC5. 
The stepwise changes of the intranodular blood supply in parallel with the 
elevation of the grade of malignancy of these hepatocellular nodules have been 
previously verified5. According to computed tomography (CT) during arterial 
portography (CTAP) and CT during hepatic arteriography (CTHA), borderline lesions 
commonly demonstrate an abundant internal portal supply on CTAP, and no 
definitely-increased arterial supply (hypovascular) on CTHA. When these lesions 
progress to hypervascular classic HCC, a hypervascular focus is almost always seen in 
the nodule on CTHA5. Therefore, the background hypovascular borderline lesion around 
the hypervascular focus is clinically considered to be a high-risk borderline lesion and is 
highly suspicious for early HCC. In addition, histological and genetic analyses revealed 
that these background borderline lesions were usually early HCC6. Diagnostic imaging 
of these high-risk background borderline lesions is therefore clinically important; 
however, the ultrasound, conventional CT, and magnetic resonance imaging (MRI) 
features of these lesions are similar to those of well-differentiated HCC, high-grade DN, 
or  more benign lesions such as low-grade DN and large, regenerative nodules 7.  
Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid 
(Gd-EOB-DTPA) is a new liver-specific contrast agent for use in MRI. This contrast 
agent accumulates in normally functioning hepatocytes in the delayed phase 
(hepatobiliary phase), which begins 10 to 20 min after injection 8. It has been reported 
that the detectability of early-stage HCCs and some borderline lesions was extremely 
high using Gd-EOB-DTPA-enhanced MRI compared to other imaging methods8. 
Therefore, it is believed that this new contrast agent may enable good detection and 
characterization of early HCC and high-risk borderline lesions.  
The purpose of this study was to assess the imaging features of hypovascular 
borderline lesions containing hypervascular foci on Gd-EOB-DTPA-enhanced MRI, and 
to evaluate the ability of Gd-EOB-DTPA-enhanced MRI to diagnose high-risk borderline 
lesions possibly consistent with early HCC. 
 
MATERIALS AND METHODS 
Institutional review board approval was obtained for this retrospective analysis of 
imaging findings. Informed consent was obtained from all patients for each examination 
and retrospective analysis of the imaging findings.  
During the period from April 2008 to June 2009, within from 217 consecutive 
patients undergoing Gd-EOB-DTPA-enhanced MRI and angiography-assisted computed 
tomography (CT) for examination of hepatocellular nodular lesions in chronic liver 
disease, a total of 73 nodules demonstrating a hypervascular focus in a borderline lesion 
(high-risk borderline lesion) were identified by CTHA and CTAP in 42 patients. The 
nodules were evaluated in this retrospective study, which comprised 30 men and 12 
women ranging in age from 56 to 87 years (mean age, 70.1 ± 7.9 years). There were 37 
patients with associated liver cirrhosis and 5 patients with chronic hepatitis, and the 
specific conditions included hepatitis B virus-related cirrhosis in 5, hepatitis C 
virus-related cirrhosis in 25, both hepatitis B- and alcoholic-related cirrhosis in 1, 
alcoholic cirrhosis in 2, nonalcoholic steatohepatitis (NASH)-related cirrhosis in 3, 
hepatitis C virus-related chronic hepatitis in 5, and non-B and non-C viral-related 
cirrhosis in 1 patient.  
All high-risk borderline lesion measurements were performed on CTHA images, 
and the largest diameter was employed for the analysis.  
Hepatobiliary phase Gd-EOB-DTBA-enhanced MRI was performed within 1 
month before or after CTAP and CTHA, and the ability of this technology to detect 
high-risk borderline nodules was analyzed.  
 
CTAP and CTHA Examinations 
CTAP and CTHA were performed after hepatic angiography combined with digital 
subtraction angiography (DFP-2000A; Toshiba, Japan) and a 64-slice multidetector row 
CT scanner (Aquilion; Toshiba) system. After femoral artery puncture, a 4-French 
catheter was selectively placed in the superior mesenteric artery for CTAP or in the 
common or proper hepatic artery for CTHA. Scanning parameters were as follows: 
number of detector rows, 64; section thickness, 0.5 mm; table feed per rotation, 7.2 mm; 
reconstruction intervals, 3 mm; gantry rotation time, 400 msec; tube voltage, 120 kVp; 
and tube current, 400 mA. For CTAP, helical CT scanning began 24 sec after an infusion 
of 50 mL of iohexol (320 mg of iodine/mL) (Omnipaque; Daiichi, Tokyo, Japan) at 1.8 
mL/sec was begun. Immediately before the injection of contrast medium, 5 μg of 
prostaglandin E1 (Palux; Taisyo, Tokyo, Japan) was injected into the superior 
mesenteric artery.  
Approximately 10 min after CTAP was performed, CTHA was obtained with 
3-mm reconstruction intervals. CTHA began 7 sec after injection of iohexol (320 mg 
iodine/mL) at 2 mL/sec was begun. The infusion continued throughout CT data 
acquisition. Angiographic procedures were performed by radiologists who each had 
more than 8 years of experience performing abdominal angiography.  
 
MR Imaging 
All individuals underwent MR imaging of the liver using a 1.5- or 3-Tesla MR system 
(Signa HDx; GE Healthcare, Milwaukee, Wis., USA). For signal reception in all 
examinations, an 8-channel anteroposterior phased-array surface coil covering the 
entire liver was placed around the patient.  
Imaging protocols included unenhanced sequences (coronal single-shot fast 
spin-echo [SSFSE], transaxial T2-weighted fast spin-echo [FSE], in- and out-of-phase 
gradient-echo[(GRE]), dynamic GRE sequences in the arterial, portal-venous and 
extracellular phases, as well as delayed sequences (30–35 sec, 65–70 sec, 3 min, and 20 
min respectively.). Each patient received an intravenous bolus injection of 
Gd-EOB-DTPA (Primovist; Bayer Schering Pharma, Osaka, Japan) as contrast agent at 
a dose of 25 μmol/kg body weight at a flow rate of 2 mL/sec, followed by a 20-mL saline 
flush. Dynamic as well as delayed imaging were performed using a fat-suppressed 3D 
T1-weighted GRE sequence employing parallel imaging (LAVA EFGRE ASSET 
breathhold: TR/TE=3.1 msec/1.4 msec; flip angle, 15°; field of view, 42 × 42 cm; matrix, 
384 × 256, interpolated to 512 × 512; thickness, 4 mm; overlap 2 mm; ASSET 
acceleration, 2.0). All patients underwent delayed MR imaging 20 min after bolus 
administration of Gd-EOB-DTPA. 
 
Image Evaluation 
A “borderline lesion” diagnosis was used for a CTAP image demonstrating an 
intranodular portal supply, and decreased arterial supply relative to the surrounding 
liver seen in greater than half the nodule on a CTHA image. When a CTHA image 
indicated a region of hyperdensity relative to the surrounding area of the nodule, it was 
defined as a “hypervascular focus”, and the borderline lesion which contained it was 
defined as a “high-risk borderline lesion”.   
All images were interpreted retrospectively by 3 experienced radiologists (one 
with more than 10 and the others with more than 20 years of experience each in liver 
imaging). Each CT and MR image was evaluated with the interpreting radiologist 
blinded to the findings of the other imaging examination, and all images were analyzed 
subjectively and independently by these 3 radiologists. Disagreements were resolved by 
consensus. Interobserver correlation was not analyzed because of the simplicity of the 
image interpretation.  
Hepatobiliary phase image finding of Gd-EOB-DTPA-enhanced MRI of the 
hypovascular part of high-risk borderline lesions were divided into the following three 
categories; hypointense compared to background liver, iso-intense with background liver, 
and hyperintense compared to background liver.  
 
Follow up Study 
Transition rate from high-risk borderline lesion to HCC was calculated with the 
Kaplan-Meier method among each findings of nodules seen on hepatobiliary phase 
Gd-EOB-DTPA-enhanced MRI. HCC diagnosis was based on the AASLD guidelines for 
the management of HCC using follow up CT and MRI 9. 
 
Statistics 
Student t test was used to compare the size of high-risk borderline lesions, and log-rank 
(mantle-Cox) method was applied for comparison of transition rate from high-risk 




The mean largest diameter of 73 high-risk borderline HCC lesions detected on 
angiography-assisted CT was 13.7 ± 3.3 mm in diameter (ranged from 9 to 20 mm), and 
the mean largest diameter of hypervascular foci was 3.3 mm. 
On hepatobiliary phase Gd-EOB-DTPA-enhanced T1-weighted MRI, 59 of the 
73 high-risk borderline lesions were hypointense (80.8%, Fig. 1) and 14 were isointense 
(19.2%, Fig. 2), compared to background liver parenchyma. The mean largest diameter 
of the 59 hypointense high-risk borderline lesions was 13.7 ± 3.4 mm and of the 14 
isointense high-risk borderline lesions was 13.7 ± 3.0 mm (P = 0.99, t-test).  
Of the 73 hypovascular high-risk borderline lesions, 46 were treated using 
ultrasonography-assisted radiofrequency ablation (RFA) therapy, and 27 nodules that 
could not be easily seen on ultrasonography were followed using multiphasic 
contrast-enhanced CT and/or MRI. Among these nodules, 18 appeared hypointense and 
9 appeared isointense on hepatobiliary phase Gd-EOB-DTPA-enhanced MRI. Nine of 
the 18 (50%) hypointense high-risk borderline lesions progressed to hypervascular HCC 
over a follow-up period of 1 to 16 months, and 5 of 9 (56%) isointense high-risk 
borderline lesions progressed to hypervascular HCC over a follow-up period of 4 to 18 
months (Figs. 3, 4). There was no significant difference between the rates of transition 
from high-risk borderline lesions to HCC for the hypointense and isointense nodules 
seen on hepatobiliary phase Gd-EOB-DTPA-enhanced MRI (P = 0.59) (Fig. 5). 
Comparing between nodules rapid transformation into HCC (1-9 months) and 
those transforming later (10 -18 months), there were no statistically significant 
differences in nodule size (rapid group 12.9±3.5 mm, later group 12.3±3.3 mm, p=0.74) 




Cirrhosis is the strongest predisposing factor for HCC, with approximately 80% of HCC 
cases arising in a cirrhotic liver. The annual incidence of HCC is 2.0% – 6.6% in patients 
with cirrhosis compared to 0.4% in patients without cirrhosis 10. The development of 
HCC in the cirrhotic liver is described either as de novo hepatocarcinogenesis or as a 
multistep progression, from low-grade dysplastic nodule to high-grade dysplastic nodule, 
to dysplastic nodule with microscopic foci of HCC, to small HCC, and finally to overt 
carcinoma11, 12.  
Angiography-assisted CT, including CTAP and CTHA, is a useful method for 
analyzing the hemodynamic characteristics of hepatic nodular lesions. According to 
previous analyses of cirrhotic nodule hemodynamics by angiography-assisted CT 13,14 
and histological studies 15,16, the hemodynamics of the portal tract, including the normal 
portal vein (intranodular portal supply) and hepatic artery (intranodular arterial 
supply through normal hepatic arteries) are decreased in relation to the elevation of 
nodule malignancy grade. On the other hand, abnormal vascularization (intranodular 
arterial supply through newly formed abnormal arteries) gradually increases.  
Therefore we can estimate nodule malignancy grade by assessing the 
intranodular blood supply. Determining this blood supply pattern is important for the 
early detection, characterization, and treatment of early-stage HCC 13, 14.  
Histopathological differential diagnosis still has problems. Based on the 
consensus document of the International Consensus Group for Hepatocellular 
Neoplasia (ICGHN), differentiating an early HCC (small well-differentiated HCC of 
vaguely nodular type) from a high-grade dysplastic nodule (H-DN) remains difficult. 
The presence of stromal invasion in the histopathological specimen is the key criterion 
for differentiation of H-DN from early HCC 17.  
Since hepatocellular invasion of intranodular portal tracts is usually a subtle 
microscopic histopathological finding, unless invasion obstructs the portal venous 
branch or hepatic arterial branch in the portal tract, it may be difficult to demonstrate 
stromal invasion in hepatocellular nodules by current radiological imaging technology 
based on intranodular hemodynamic analysis. Therefore, with the current imaging 
modalities, we believe it may be difficult to differentiate early HCC from H-DN 
according to the histopathological criteria, and we need to use different criteria for the 
screening of early-stage HCC by diagnostic imaging. 
Our study using angiography-assisted CT revealed that there was a close 
correlation between the prognosis of hepatic nodules and blood supply patterns. 
According to that previous analysis, all completely hypovascular nodules with 
hypervascular foci progressed to completely hypervascular nodules (hypervascular 
classical HCC) within approximately 900 days (malignant transformation). By contrast, 
only approximately 30% of nodules without hypervascular foci (= hypovascular 
borderline lesion) progressed to classical HCC during the same period, and 
hypervascular foci appeared in all of those progressing nodules before their progression 
to classical HCC 5.  
Yu et al [18] have also reported that identification of a hypervascular focus in a 
nonhypervascular nodule is essential for considering short-term follow-up or immediate 
treatment of HCC.  
Therefore, we have believed that for early detection and treatment of 
hypervascular classical HCC, detecting hypovascular cirrhotic nodules with 
hypervascular foci (high-risk borderline nodule) using angiography-assisted CT is 
important.  
However, angiography-assisted CT, including CTHA and CTAP, is not widely 
performed for an in depth examination of the cirrhotic liver, because it is a more 
invasive imaging modality than intravenous contrast-enhanced CT and MRI. We need 
to develop a less invasive imaging method to differentiate high-risk borderline nodules 
from various kinds of cirrhotic nodules. 
Gd-EOB-DTPA is a novel liver-specific contrast agent for MRI. This contrast 
agent accumulates in normally functioning hepatocytes in the delayed phase 
(hepatobiliary phase) which begins 10 to 20 min after injection. Therefore, we can 
assess the functioning status of cirrhotic nodules on hepatobiliary phase 
Gd-EOB-DTPA-enhanced MRI, which we could not do using conventional iodine 
contrast material for CT and Gd-DTPA contrast material for MRI.  
Although it is well known that most hepatocellular carcinomas appear 
hypointense compared to background liver parenchyma on hepatobiliary phase 
Gd-EOB-DTPA-enhanced MRI8, the imaging findings of hepatocellular carcinoma 
borderline lesions on hepatobiliary phase Gd-EOB-DTPA-enhanced MRI have not been 
well clarified. 
In our preliminary analysis, 50% of hypovascular borderline lesion “without” 
hypervascular foci, showed isointensity, 30% showed hypointensity, and 20% showed 
hyperintensity on hepatobiliary phase of Gd-EOB-DTPA enhanced MRI (unpublished 
data). 
In this study, we defined a hypovascular borderline lesion containing 
hypervascular foci detected on angiography-assisted CT as a “high-risk borderline 
lesion”, and we have revealed that on hepatobiliary phase Gd-EOB-DTPA-enhanced 
MRI, 80.8% of high-risk borderline lesions appear hypointense compared to background 
liver parenchyma.  
This high-risk borderline lesion detection rate of hepatobiliary phase 
Gd-EOB-DTPA-enhanced MRI is better than the rates of modalities previously reported 
by Shinmura et al, including dynamic contrast-enhanced CT, dynamic 
contrast-enhanced MR, and SPIO-enhanced MR 19.  
In addition, follow-up study of high-risk borderline lesions found that 50% of 
hypointense nodules and 56% of isointense nodules seen by hepatobiliary phase 
Gd-EOB-DTPA-enhanced MRI transformed into hypervascular HCC within a follow-up 
period of 1 to 18 months. There was no significant difference between the transition 
rates to hypervascular HCC between the hypointense and isointense nodules. These 
results indicate that both the hypo- and isointense nodules have similar degrees of 
malignant potential. Therefore it is important to note that not only hypointense, but 
also isointense nodules seen on hepatobiliary phase Gd-EOB-DTPA-enhanced MRI may 
transform to hypervascular HCC.  
There are several limitations to this study. Since all the objective cases have 
definite hypervascular HCC in other part of the liver, we did not perform core needle 
biopsy for diagnose of these borderline lesions. So there were no histopathological 
confirmations of the borderline lesions and HCCs in this study.  Another limitation is 
that, in this study, although we focused on the borderline lesions with hypervascular 
foci, some regions of borderline lesions without hypervascular foci may transform to 
hypervascular HCC. We have no data about the sensitivity/specificity of the detection 
rate of hypervascular foci on angiography-assisted CT and other intravenous contrast 
enhanced images. In addition, regarding the follow-up analysis determining the 
transformation rate from high-risk borderline lesion to hypervascular HCC, because the 
number of nodules studied was low, there may be some bias in our results.  
Although there are several study limitations, the results of our study indicate 
that for early detection and treatment of many hypervascular HCCs, it is important to 
follow hypovascular nodules which appear hypointense on hepatobiliary phase 
Gd-EOB-DTPA-enhanced MRI until they reveal staining on dynamic contrast-enhanced 
CT or MRI. However, it is important to point out that some high-risk borderline lesions 
appearing isointense on hepatobiliary phase Gd-EOB-DTPA-enhanced MRI also 
transformed into hypervascular HCC. So it would be better to use angiography-assisted 
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Fig.1 Hypovascular borderline HCC lesion with hypervascular foci (high-risk borderline 
lesion) in an 81-year-old man with cirrhotic liver from chronic B-viral hepatitis. 
(a): Transverse CTAP shows isodense lesion (arrow) with a small hypodense spot 
(arrowhead) in segment III of the liver. 
(b): Transverse CTHA shows an area of spotty hyperdensity (arrowhead) within a 
hypodense nodule (arrow). 
(c): Transverse T1-weighted image of hepatobiliary phase of Gd-EOB-DTPA-enhanced 
MRI shows hypointense nodule (arrow) containing an area of spotty isointensity 
(arrowhead) which corresponds to a hyperdense area on CTHA. 
 
Fig.2 Hypovascular borderline HCC lesion with hypervascular foci (high-risk borderline 
lesion) in a 58-year-old female with cirrhotic liver from chronic C-viral hepatitis. 
(a): Transverse CTAP shows isodense lesion (arrow) with a small hypodense spot 
(arrowhead) in segment II of the liver. 
(b): Transverse CTHA shows an area of spotty hyperdensity (arrowhead) within a 
hypodense nodule (arrow). 
(c): Transverse T1-weighted image of hepatobiliary phase of Gd-EOB-DTPA-enhanced 
MRI shows an area of isointensity which is difficult to identify as a nodular lesion 
without other imaging findings (arrow). 
 
Fig.3 Hypovascular borderline HCC lesion with hypervascular foci (high-risk borderline 
lesion) in a 66-year-old female with cirrhotic liver from chronic C-viral hepatitis. 
(a): Transverse CTHA shows an area of spotty hyperdensity (arrowhead) within a 
hypodense nodule (arrow). 
(b): Transverse T1-weighted image of hepatobiliary phase of Gd-EOB-DTPA-enhanced 
MRI shows isointense nodule(arrow) containing an area of spotty hypointensity 
(arrowhead) which corresponds to hyperdense area on CTHA. 
(c) Transverse arterial phase-enhanced CT 5 months after the initial EOB study shows 
well-attenuated mass lesion corresponding to the previous hypodense nodule (arrow). 
(d): Transverse T1-weighted image of hepatobiliary phase Gd-EOB-DTPA-enhanced 
MRI 5 months after the initial EOB-enhanced study shows hypointense nodule (arrow). 
 
Fig.4 Hypovascular borderline HCC lesion with hypervascular foci (high-risk borderline 
lesion) in a 59-year-old man with cirrhotic liver from chronic C-viral hepatitis. 
(a): Transverse CTHA shows a spotty area of hyperdensity (arrowhead) within a 
hypodense nodule (arrow). 
(b): Transverse T1-weighted image of hepatobiliary phase of Gd-EOB-DTPA-enhanced 
MRI shows hypointense nodule (arrow). 
(c); Arterial phase contrast-enhanced transverse CT, 4 months after the initial 
EOB-enhanced study, shows early contrast enhancement in the right lobe of the liver 
(arrow). 
 
Fig.5 Graph shows nonmalignant transformation curves (calculated by Kaplan-Meier 
method) for both hypointense and isointense nodules on hepatobiliary phase of 
contrast-enhanced MRI. 














